Boston Consulting Group is naming a new chief risk officer and putting other client-selection protocols in place after months of controversy stemming from its work on an Israeli-backed ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

bDepartment of Medical Oncology, IRCCS San Raffaele Hospital, Comprehensive Cancer Center, Milan, Italy cDepartment of Urology, IRCCS San Raffaele Hospital, Comprehensive Cancer Center, Milan, Italy ...

At the Global Cybersecurity Forum (GCF) 2025 in Riyadh, Boston Consulting Group and GCF unveiled The Quantum Leap: Navigating the Future of Computing, a comprehensive study examining how quantum ...

Inlexzo is an intravesical gemcitabine releasing system that is inserted directly into the bladder through a urinary catheter. The Food and Drug Administration (FDA) has approved Inlexzo ™ ...

You can create a release to package software, along with release notes and links to binary files, for other people to use. Learn more about releases in our docs.

Laurence Fishburne has addressed whether he might step back into the role of Morpheus for The Matrix 5. Appearing at New York Comic Con 2025 for The Matrix reunion panel, the actor said that he is ...

(UroToday.com) The 2025 ESMO annual meeting featured a urothelial carcinoma proffered paper session and a presentation by Dr. Maria De Santis discussing POTOMAC, a phase 3, randomized, open-label, ...

With last year’s news about “The Martian” screenwriter Drew Goddard taking the helm from Lana and Lily Wachowski for a new “Matrix” film, Laurence Fishburne expressed his hesitancy in reprising his ...

(UroToday.com) The 2025 ESMO annual meeting featured a urothelial carcinoma proffered paper session and a presentation by Dr. Morgan Roupret discussing ALBAN, a phase 3, randomized, open-label, ...